Every 10-Q that Creative Medical Technology Holdings, Inc. (CELZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CELZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELZ filings page.
Creative Medical Technology Holdings, Inc. reported no revenue for the quarter ended June 30, 2026 and a net loss of $1.5 million, compared with a $1.2 million loss a year earlier. For the first six months of 2026, the net loss was $2.9 million, similar to the prior‑year period, as the company continued to fund clinical development and corporate operations.
Research and development expenses were $459,200 for the quarter and $1.0 million year‑to‑date, lower than 2025 as the CELZ‑201 ADAPT trial moved from recruitment and dosing to follow‑up. Selling, general and administrative expenses increased to $1.1 million for the quarter and $2.0 million year‑to‑date, driven by marketing, salaries, legal and travel.
Cash and equivalents were $8.7 million at June 30, 2026, up from $7.2 million at year‑end, supported by $4.5 million of proceeds from June warrant exercises, leaving working capital of about $8.3 million. The company highlighted progress on its regenerative platforms, including the Olastrocel™ (CELZ‑201) Phase 1/2 ADAPT trial with FDA Fast Track designation, Ultrasome™ pilot data in knee osteoarthritis, and the CELZ Biodefense Project PHOENIX burn‑pit registry.
Creative Medical Technology Holdings reported a net loss of $1.4 million for the quarter ended March 31, 2026, slightly improved from $1.6 million a year earlier, as it reduced research and development spending.
Revenue was negligible, with no sales this quarter versus $3,000 in the prior-year period. Cash and cash equivalents totaled $5.7 million, down from $7.2 million at year-end, after using $1.3 million in operating cash and $175,000 for investments, including a related-party SPAC initiative and convertible notes.
The company continues to focus on its regenerative medicine pipeline, highlighting progress in AlloStemSpine® chronic lower back pain trials, CELZ-201 programs for Type 1 diabetes, and collaborations using induced pluripotent stem cells and artificial intelligence.
Creative Medical Technology Holdings (CELZ) filed its Q3 2025 10‑Q, showing continued operating investment and recent warrant-driven funding. Cash was $5.38 million at September 30, 2025, with positive working capital of about $5.15 million. Q3 net loss was $1.24 million (vs. $1.04 million a year ago), and the nine‑month net loss was $4.11 million. Revenue remained minimal at $3,000 year-to-date.
Operating expenses reflected higher selling, general and administrative costs, partly offset by lower R&D as the AlloStemSpine ADAPT trial moved through recruitment. The company raised approximately $3.7 million in March 2025 via warrant exercise inducements; a subsequent October 25, 2025 inducement generated about $3.8 million in net proceeds, with those new warrants’ exercise price reset to $2.86 on November 4, 2025 based on VWAP mechanics. Warrants outstanding were 4,147,478 at quarter-end.
As of November 1, 2025, CELZ had 2,580,532 common shares outstanding. Management highlighted progress across clinical programs and maintained effective disclosure controls.
Creative Medical Technology Holdings, Inc. reported cash and short-term investments of $6,544,120 and total assets of $7,105,228 at June 30, 2025, with positive working capital of approximately $6,355,063 and stockholders' equity of $6,827,584. The company remains unprofitable, recording a six-month net loss of $2,871,400 versus $2,599,272 a year earlier.
Commercial revenue was minimal: $0 for the quarter and $3,000 for the six months, down from $8,000 a year ago. Operating loss for the six months was $2,923,998. Research and development expense for the six months totaled $1,244,565 while selling, general and administrative expense was $1,619,914. Basic net loss per share for six months was $(1.26) on a weighted average of 2,282,290 shares.
The company strengthened liquidity through warrant exercises and related financings, generating approximately $3.7 million of net proceeds during the period and reporting 4,147,478 warrants outstanding at June 30, 2025. Clinical programs show material progress: an independent Data Safety Monitoring Board completed a safety review and recommended continuation of the CELZ-201 ADAPT trial after initial cohorts, and the company completed dosing of the second cohort (20 patients total) in Q2 2025.